Nov. 20, 2019 Price forecast | 2 weeks: 5.90% | 1 month: 6.81% | 3 months: 7.18%


AKBA stock forecast

Our latest prediction for Akebia Therapeutics, Inc.'s stock price was made on the Nov. 20, 2019 when the stock price was at 3.34$.

In the short term (2weeks), AKBA's stock price should outperform the market by 5.90%. During that period the price should oscillate between -7.35% and +13.91%.

In the medium term (3months), AKBA's stock price should outperform the market by 7.18%. During that period the price should oscillate between -17.29% and +38.45%.


About Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

At the moment the company generates 325M USD in revenues.

On its last earning announcement, the company reported a loss of -2.50$ per share.

The book value per share is 2.91$

Akebia Therapeutics, Inc. website


Three months stock forecastNov. 20, 2019


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
325M 64.70% -282M -86.60% -245M -2.50 - - 106M 2.91 -239M -7M -246M